SERUM ALBUMIN
OrganismNot specified
State in the Current Structure
| Assembly | Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Associated Components | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|
| 1 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain A； UniProt 25–609 | Not recorded | No other associated polymer | X-RAY DIFFRACTION X-ray crystallization conditions：pH 7.5；PROTEIN WAS CRYSTALLIZED FROM 22-25% PEG 3350, 50 MM POTASSIUM PHOSPHATE, PH 7.0-7.5. | Resolution 2.50 Å R-free 0.282 |
| 2 | Protein monomer Monomer Protein × 1 PDB declaration: monomeric（1） Consistent with protein copy count | Chain B； UniProt 25–609 | Not recorded | No other associated polymer | X-RAY DIFFRACTION X-ray crystallization conditions：pH 7.5；PROTEIN WAS CRYSTALLIZED FROM 22-25% PEG 3350, 50 MM POTASSIUM PHOSPHATE, PH 7.0-7.5. | Resolution 2.50 Å R-free 0.282 |
Other States of the Same Protein in the Database
Each row is a biological assembly of the same UniProt protein in another PDB entry. The “Difference from current entry” column identifies evidence-level differences; no tag means the currently parsed fields agree.
| Other PDB | Difference from Current Entry 1AO6 | Assembly / Oligomeric State | Construct | Mutations and Modifications | Ligands, Ions and Non-polymers | Method and Experimental Conditions | Structure Quality |
|---|---|---|---|---|---|---|---|
| 1BJ5 HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID Deposited 1998-07-02 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
vapor diffusion - sitting drop with streak and macroseeding；pH 7.5；CRYSTALS WERE OBTAINED BY VAPOUR DIFFUSION USING THE SITTING DROP TECHNIQUE. EQUAL VOLUMES OF HSA-MYRISTIC ACID COMPLEX (100 MG/ML) WERE MIXED WITH A RESERVOIR SOLUTION CONSISTING OF 25-30% (W/ V) POLYETHYLENE GLYCOL 3350, 50MM POTASSIUM PHOSPHATE PH 7.5. CRYSTALS GREW SPONTANEOUSLY AS CLUSTERS OF RODS. STREAK AND MACROSEEDING WERE USED TO INCREASE CRYSTAL YIELD. CRYSTALS WERE HARVESTED INTO 31% (W/V) PEG 3350, 50MM POTASSIUM PHOSPHATE PH 7.5 CONTAINING 0.1 MM MYRISTIC ACID., vapor diffusion - sitting drop with streak and macroseeding
|
Resolution 2.50 Å R-free 0.279 |
| 1BKE HUMAN SERUM ALBUMIN IN A COMPLEX WITH MYRISTIC ACID AND TRI-IODOBENZOIC ACID Deposited 1998-07-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–608（581 aa）
|
Not recorded | MYR MYRISTIC ACID × 5 B3I 2,3,5-TRIIODOBENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 3.15 Å R-free 0.248 |
| 1BM0 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN Deposited 1998-07-28 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.50 Å R-free 0.292 |
| 1BM0 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN Deposited 1998-07-28 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.5；pH 7.5
|
Resolution 2.50 Å R-free 0.292 |
| 1E78 Crystal structure of human serum albumin Deposited 2000-08-25 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.60 Å R-free 0.277 |
| 1E78 Crystal structure of human serum albumin Deposited 2000-08-25 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.60 Å R-free 0.277 |
| 1E7A Crystal structure of human serum albumin complexed with the general anesthetic propofol Deposited 2000-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | PFL 2,6-BIS(1-METHYLETHYL)PHENOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.20 Å R-free 0.272 |
| 1E7A Crystal structure of human serum albumin complexed with the general anesthetic propofol Deposited 2000-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | PFL 2,6-BIS(1-METHYLETHYL)PHENOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.20 Å R-free 0.272 |
| 1E7B Crystal structure of human serum albumin complexed with the general anesthetic halothane Deposited 2000-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | HLT 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.38 Å R-free 0.303 |
| 1E7B Crystal structure of human serum albumin complexed with the general anesthetic halothane Deposited 2000-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | HLT 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.38 Å R-free 0.303 |
| 1E7C HUMAN SERUM ALBUMIN COMPLEXED WITH MYRISTIC ACID and the general anesthetic halothane Deposited 2000-08-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 5 HLT 2-BROMO-2-CHLORO-1,1,1-TRIFLUOROETHANE × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.40 Å R-free 0.282 |
| 1E7E HUMAN SERUM ALBUMIN COMPLEXED WITH DECANOIC ACID (CAPRIC ACID) Deposited 2000-08-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | DKA DECANOIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.50 Å R-free 0.271 |
| 1E7F HUMAN SERUM ALBUMIN COMPLEXED WITH DODECANOIC ACID (LAURIC ACID) Deposited 2000-08-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | DAO LAURIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.43 Å R-free 0.276 |
| 1E7G Human serum albumin complexed with tetradecanoic acid (myristic acid) Deposited 2000-08-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.50 Å R-free 0.288 |
| 1E7H HUMAN SERUM ALBUMIN COMPLEXED WITH HEXADECANOIC ACID (PALMITIC ACID) Deposited 2000-08-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | PLM PALMITIC ACID × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.43 Å R-free 0.272 |
| 1E7I HUMAN SERUM ALBUMIN COMPLEXED WITH OCTADECANOIC ACID (STEARIC ACID) Deposited 2000-08-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | STE STEARIC ACID × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.70 Å R-free 0.258 |
| 1GNI HUMAN SERUM ALBUMIN COMPLEXED WITH cis-9-OCTADECENOIC ACID (OLEIC ACID) Deposited 2001-10-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | OLA OLEIC ACID × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.40 Å R-free 0.242 |
| 1GNJ HUMAN SERUM ALBUMIN COMPLEXED WITH cis-5,8,11,14-EICOSATETRAENOIC ACID (ARACHIDONIC ACID) Deposited 2001-10-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | ACD ARACHIDONIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.60 Å R-free 0.245 |
| 1H9Z Human Serum Albumin Complexed With Myristic Acid and the R-(+) enantiomer of warfarin Deposited 2001-03-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 RWF R-WARFARIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.50 Å R-free 0.255 |
| 1HA2 Human Serum Albumin Complexed With Myristic Acid and the S-(-) enantiomer of warfarin Deposited 2001-03-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 SWF S-WARFARIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PUBLICATION, pH 7.00
|
Resolution 2.50 Å R-free 0.247 |
| 1HK1 HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) Deposited 2003-03-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.65 Å R-free 0.252 |
| 1HK2 HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) Deposited 2003-03-05 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Mutation：YES | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.80 Å R-free 0.244 |
| 1HK3 Human serum albumin mutant r218p complexed with thyroxine (3,3',5,5'-tetraiodo-l-thyronine) Deposited 2003-03-05 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Mutation：YES | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.80 Å R-free 0.245 |
| 1HK4 HUMAN SERUM ALBUMIN COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) and myristic acid (tetradecanoic acid) Deposited 2003-03-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.40 Å R-free 0.267 |
| 1HK5 HUMAN SERUM ALBUMIN MUTANT R218H COMPLEXED WITH THYROXINE (3,3',5,5'-TETRAIODO-L-THYRONINE) and myristic acid (tetradecanoic acid) Deposited 2003-03-05 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Mutation：YES | MYR MYRISTIC ACID × 7 T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.70 Å R-free 0.259 |
| 1N5U X-RAY STUDY OF HUMAN SERUM ALBUMIN COMPLEXED WITH HEME Deposited 2002-11-07 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 5 HEM PROTOPORPHYRIN IX CONTAINING FE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, potassium phosphate, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 1.90 Å R-free 0.280 |
| 1O9X HUMAN SERUM ALBUMIN COMPLEXED WITH TETRADECANOIC ACID (MYRISTIC ACID) AND HEMIN Deposited 2002-12-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 HEM PROTOPORPHYRIN IX CONTAINING FE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.20 Å R-free 0.288 |
| 1TF0 Crystal structure of the GA module complexed with human serum albumin Deposited 2004-05-26 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
25–596（572 aa）
|
Not recorded | DKA DECANOIC ACID × 3 CIT CITRIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6；291 K；Ammonium sulfate, citrate, pH 6.0, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.70 Å R-free 0.295 |
| 1UOR X-RAY STUDY OF RECOMBINANT HUMAN SERUM ALBUMIN. PHASES DETERMINED BY MOLECULAR REPLACEMENT METHOD, USING LOW RESOLUTION STRUCTURE MODEL OF TETRAGONAL FORM OF HUMAN SERUM ALBUMIN Deposited 1998-03-10 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.0
|
Resolution 2.80 Å |
| 1YSX Solution structure of domain 3 from human serum albumin complexed to an anti-apoptotic ligand directed against Bcl-xL and Bcl-2 Deposited 2005-02-09 | Different construct Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
409–609（201 aa）
|
Not recorded | 4EB 4-({2-[(2,4-DIMETHYLPHENYL)SULFANYL]ETHYL}AMINO)-N-[(4'-FLUORO-1,1'-BIPHENYL-4-YL)CARBONYL]-3-NITROBENZENESULFONAMIDE × 1 |
SOLUTION NMR
NMR measurement conditions
pH 6.5；303 K；Ionic strength (raw mmCIF value) 200 mM；Pressure ambient
NMR sample composition
0.5 mM Human serum albumin domain 3 U-15N,13C, 50 mM sodium phosphate, 150 mM sodium chloride, 0.1 mM EDTA, 100% D2O | 100% D2O
|
Resolution not provided |
| 21TV Cryo-EM structure of the TNF-alpha-Ozoralizumab (OZR)-HSA complex Deposited 2025-12-26 | Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain E
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 6.19 Å |
| 2BX8 Human serum albumin complexed with azapropazone Deposited 2005-07-25 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | AZQ AZAPROPAZONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.70 Å R-free 0.273 |
| 2BX8 Human serum albumin complexed with azapropazone Deposited 2005-07-25 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | AZQ AZAPROPAZONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.70 Å R-free 0.273 |
| 2BXA Human serum albumin complexed with 3-carboxy-4-methyl-5-propyl-2- furanpropanoic acid (CMPF) Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | C1F 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.35 Å |
| 2BXA Human serum albumin complexed with 3-carboxy-4-methyl-5-propyl-2- furanpropanoic acid (CMPF) Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | C1F 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPIONIC × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.35 Å |
| 2BXB Human serum albumin complexed with oxyphenbutazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | OPB 4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYLPYRAZOLIDINE-3,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.20 Å R-free 0.276 |
| 2BXB Human serum albumin complexed with oxyphenbutazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | OPB 4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYLPYRAZOLIDINE-3,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.20 Å R-free 0.276 |
| 2BXC Human serum albumin complexed with phenylbutazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | P1Z 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.10 Å R-free 0.291 |
| 2BXC Human serum albumin complexed with phenylbutazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | P1Z 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.10 Å R-free 0.291 |
| 2BXD Human serum albumin complexed with warfarin Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | RWF R-WARFARIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.05 Å R-free 0.259 |
| 2BXD Human serum albumin complexed with warfarin Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | RWF R-WARFARIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 3.05 Å R-free 0.259 |
| 2BXE Human serum albumin complexed with diflunisal Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.95 Å R-free 0.270 |
| 2BXE Human serum albumin complexed with diflunisal Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 1FL 5-(2,4-DIFLUOROPHENYL)-2-HYDROXY-BENZOIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.95 Å R-free 0.270 |
| 2BXF Human serum albumin complexed with diazepam Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | DZP 7-CHLORO-1-METHYL-5-PHENYL-1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.95 Å R-free 0.262 |
| 2BXF Human serum albumin complexed with diazepam Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | DZP 7-CHLORO-1-METHYL-5-PHENYL-1,3-DIHYDRO-2H-1,4-BENZODIAZEPIN-2-ONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.95 Å R-free 0.262 |
| 2BXG Human serum albumin complexed with ibuprofen Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | IBP IBUPROFEN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.70 Å R-free 0.281 |
| 2BXG Human serum albumin complexed with ibuprofen Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | IBP IBUPROFEN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.70 Å R-free 0.281 |
| 2BXH Human serum albumin complexed with indoxyl sulfate Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | IOS 3-SULFOOXY-1H-INDOLE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.25 Å R-free 0.266 |
| 2BXH Human serum albumin complexed with indoxyl sulfate Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | IOS 3-SULFOOXY-1H-INDOLE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.25 Å R-free 0.266 |
| 2BXI Human serum albumin complexed with myristate and azapropazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 5 AZQ AZAPROPAZONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.50 Å R-free 0.264 |
| 2BXK Human serum albumin complexed with myristate, azapropazone and indomethacin Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 IMN INDOMETHACIN × 1 AZQ AZAPROPAZONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.40 Å R-free 0.254 |
| 2BXL Human serum albumin complexed with myristate and 3,5-diiodosalicylic acid Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 DIU 2-HYDROXY-3,5-DIIODO-BENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.60 Å R-free 0.242 |
| 2BXM Human serum albumin complexed with myristate and indomethacin Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 IMN INDOMETHACIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.50 Å R-free 0.247 |
| 2BXN Human serum albumin complexed with myristate and iodipamide Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 IDB 3-[5-[(3-CARBOXY-2,4,6-TRIIODO-PHENYL)CARBAMOYL]PENTANOYLAMINO]-2,4,6-TRIIODO-BENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.65 Å R-free 0.264 |
| 2BXO Human serum albumin complexed with myristate and oxyphenbutazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 OPB 4-BUTYL-1-(4-HYDROXYPHENYL)-2-PHENYLPYRAZOLIDINE-3,5-DIONE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.60 Å R-free 0.253 |
| 2BXP Human serum albumin complexed with myristate and phenylbutazone Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 P1Z 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.30 Å R-free 0.250 |
| 2BXQ Human serum albumin complexed with myristate, phenylbutazone and indomethacin Deposited 2005-07-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 IMN INDOMETHACIN × 2 P1Z 4-BUTYL-1,2-DIPHENYL-PYRAZOLIDINE-3,5-DIONE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；pH 7.00
|
Resolution 2.60 Å R-free 0.256 |
| 2I2Z Human serum albumin complexed with myristate and aspirin Deposited 2006-08-17 | Different mutation/modification Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) | MYR MYRISTIC ACID × 5 SAL 2-HYDROXYBENZOIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION, vapor diffusion, sitting drop；pH 7.5；293 K；31-34% (w/v) PEG 3350, 50mM potassium phosphate (pH 7.5). Crystals grew spontaneously as clusters of rods after three days. Technique of streak-seeding was used to improve crystal quality., EVAPORATION, vapor diffusion, sitting drop, temperature 293K
|
Resolution 2.70 Å R-free 0.262 |
| 2I30 Human serum albumin complexed with myristate and salicylic acid Deposited 2006-08-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | SAL 2-HYDROXYBENZOIC ACID × 2 MYR MYRISTIC ACID × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION, vapor diffusion, sitting drop；pH 7.5；293 K；31% PEG 3350, 0.05M potassium phosphate, pH 7.5, EVAPORATION, vapor diffusion, sitting drop, temperature 293K
|
Resolution 2.90 Å R-free 0.251 |
| 2N0X Three dimensional structure of EPI-X4, a human albumin-derived peptide that regulates innate immunity through the CXCR4/CXCL12 chemotactic axis and antagonizes HIV-1 entry Deposited 2015-03-18 | Different construct Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
432–447（16 aa）
Fragment：Albumin 3 domain residues 432-447
|
Not recorded | No recorded non-water small molecule |
SOLUTION NMR
NMR measurement conditions
pH 7；298 K；Pressure ambient
NMR sample composition
10 mM sodium phosphate, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided |
| 2VDB Structure of human serum albumin with S-naproxen and the GA module Deposited 2007-10-04 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
30–608（579 aa）
Fragment：RESIDUES 30-608
|
Not recorded | DKA DECANOIC ACID × 6 NPS (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
26-32% PEG 3350, 50 MM POTASSIUM PHOSPHATE, 0.1 M AMMONIUM PHOSPHATE/POTASSIUM PHOSPHATE
|
Resolution 2.52 Å R-free 0.280 |
| 2VUE Human serum albumin complexed with 4Z,15E-bilirubin-IX-alpha Deposited 2008-05-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | BLA BILIVERDINE IX ALPHA × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.42 Å R-free 0.273 |
| 2VUE Human serum albumin complexed with 4Z,15E-bilirubin-IX-alpha Deposited 2008-05-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | BLA BILIVERDINE IX ALPHA × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.42 Å R-free 0.273 |
| 2VUF Human serum albumin complexed with fusidic acid Deposited 2008-05-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | FUA FUSIDIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 3.05 Å R-free 0.250 |
| 2VUF Human serum albumin complexed with fusidic acid Deposited 2008-05-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | FUA FUSIDIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 3.05 Å R-free 0.250 |
| 2XSI Human serum albumin complexed with dansyl-L-glutamate and myristic acid Deposited 2010-10-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 9NE DANSYL-L-GLUTAMATE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.70 Å R-free 0.251 |
| 2XVQ Human serum albumin complexed with dansyl-L-sarcosine Deposited 2010-10-27 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9DS DANSYL-L-SARCOSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.90 Å R-free 0.257 |
| 2XVQ Human serum albumin complexed with dansyl-L-sarcosine Deposited 2010-10-27 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9DS DANSYL-L-SARCOSINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.90 Å R-free 0.257 |
| 2XVU Human serum albumin complexed with dansyl-L-asparagine Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9DN DANSYL-L-ASPARAGINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.60 Å R-free 0.244 |
| 2XVU Human serum albumin complexed with dansyl-L-asparagine Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9DN DANSYL-L-ASPARAGINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.60 Å R-free 0.244 |
| 2XVV Human serum albumin complexed with dansyl-L-asparagine and myristic acid Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 9DN DANSYL-L-ASPARAGINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.40 Å R-free 0.250 |
| 2XVW Human serum albumin complexed with dansyl-L-arginine and myristic acid Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 9NR DANSYL-L-ARGININE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.65 Å R-free 0.252 |
| 2XW0 Human serum albumin complexed with dansyl-L-phenylalanine Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9NF DANSYL-L-PHENYLALANINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.40 Å R-free 0.254 |
| 2XW0 Human serum albumin complexed with dansyl-L-phenylalanine Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9NF DANSYL-L-PHENYLALANINE × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.40 Å R-free 0.254 |
| 2XW1 Human serum albumin complexed with dansyl-L-norvaline Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9NV DANSYL-L-NORVALINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.50 Å R-free 0.256 |
| 2XW1 Human serum albumin complexed with dansyl-L-norvaline Deposited 2010-10-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9NV DANSYL-L-NORVALINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.50 Å R-free 0.256 |
| 2YDF HUMAN SERUM ALBUMIN COMPLEXED WITH IOPHENOXIC ACID Deposited 2011-03-18 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | IO3 IOPHENOXIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.75 Å R-free 0.239 |
| 2YDF HUMAN SERUM ALBUMIN COMPLEXED WITH IOPHENOXIC ACID Deposited 2011-03-18 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | IO3 IOPHENOXIC ACID × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7；SEE PAPER, pH 7
|
Resolution 2.75 Å R-free 0.239 |
| 3A73 Crystal Structure Analysis of Human serum albumin complexed with delta 12-prostaglandin J2 Deposited 2009-09-11 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 PJ2 (5Z,12Z,15S)-15-hydroxy-11-oxoprosta-5,9,12-trien-1-oic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；285 K；50mM phosphate buffer pH 6.5, 28-32% (w/v) PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 285K
|
Resolution 2.19 Å R-free 0.291 |
| 3A73 Crystal Structure Analysis of Human serum albumin complexed with delta 12-prostaglandin J2 Deposited 2009-09-11 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 PJ2 (5Z,12Z,15S)-15-hydroxy-11-oxoprosta-5,9,12-trien-1-oic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；285 K；50mM phosphate buffer pH 6.5, 28-32% (w/v) PEG 3350, VAPOR DIFFUSION, HANGING DROP, temperature 285K
|
Resolution 2.19 Å R-free 0.291 |
| 3B9L Human serum albumin complexed with myristate and AZT Deposited 2007-11-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 AZZ 3'-azido-3'-deoxythymidine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；32%(w/v) polyethylene glycol 3350, 50mM potassium phosphate, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 2.60 Å R-free 0.292 |
| 3B9M Human serum albumin complexed with myristate, 3'-azido-3'-deoxythymidine (AZT) and salicylic acid Deposited 2007-11-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 AZZ 3'-azido-3'-deoxythymidine × 1 SAL 2-HYDROXYBENZOIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；32%(w/v) polyethylene glycol 3350, 50mM potassium phosphate, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293.0K
|
Resolution 2.70 Å R-free 0.316 |
| 3CX9 Crystal Structure of Human serum albumin complexed with Myristic acid and lysophosphatidylethanolamine Deposited 2008-04-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–608（582 aa）
Fragment：UNP residues 27-608
|
Not recorded | MYR MYRISTIC ACID × 5 LPX (2S)-3-{[(R)-(2-aminoethoxy)(hydroxy)phosphoryl]oxy}-2-hydroxypropyl hexadecanoate × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；35% PEG 3350, 85mM potassium phosphate, 5mM sodium azide, pH7.5, VAPOR DIFFUSION, SITTING DROP, temperature 298.0K
|
Resolution 2.80 Å R-free 0.295 |
| 3JQZ Crystal Structure of Human serum albumin complexed with Lidocaine Deposited 2009-09-08 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
25–609（585 aa）
Chain B
25–609（585 aa）
|
Not recorded | LQZ 2-(diethylamino)-N-(2,6-dimethylphenyl)ethanamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；20-21% polyethylene glycol 6000, 9-10% ethylene glycol, 50/100mM ammonium acetate, 2% 2-methyl-2,4-pentanediol, 50mM Tris-HCl, pH7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 3.30 Å R-free 0.268 |
| 3JRY Human Serum albumin with bound Sulfate Deposited 2009-09-09 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；22-25% PEG 3350, 100-200mM ammonium sulphate and 50mM Tris-HCl, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 2.30 Å R-free 0.268 |
| 3JRY Human Serum albumin with bound Sulfate Deposited 2009-09-09 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | SO4 SULFATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；292 K；22-25% PEG 3350, 100-200mM ammonium sulphate and 50mM Tris-HCl, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 292K
|
Resolution 2.30 Å R-free 0.268 |
| 3LU6 Human serum albumin in complex with compound 1 Deposited 2010-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | IMX [(1R,2R)-2-{[(5-fluoro-1H-indol-2-yl)carbonyl]amino}-2,3-dihydro-1H-inden-1-yl]acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；PEG, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å R-free 0.275 |
| 3LU6 Human serum albumin in complex with compound 1 Deposited 2010-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | IMX [(1R,2R)-2-{[(5-fluoro-1H-indol-2-yl)carbonyl]amino}-2,3-dihydro-1H-inden-1-yl]acetic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；PEG, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.70 Å R-free 0.275 |
| 3LU7 Human serum albumin in complex with compound 2 Deposited 2010-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | IPX 4-[(1R,2R)-2-{[(5-fluoro-1H-indol-2-yl)carbonyl]amino}-2,3-dihydro-1H-inden-1-yl]butanoic acid × 1 PO4 PHOSPHATE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；PEG, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.276 |
| 3LU7 Human serum albumin in complex with compound 2 Deposited 2010-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | IPX 4-[(1R,2R)-2-{[(5-fluoro-1H-indol-2-yl)carbonyl]amino}-2,3-dihydro-1H-inden-1-yl]butanoic acid × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；PEG, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.80 Å R-free 0.276 |
| 3LU8 Human serum albumin in complex with compound 3 Deposited 2010-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | IQX N-[5-(5-{[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino}-6-fluoropyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；PEG, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.60 Å R-free 0.266 |
| 3LU8 Human serum albumin in complex with compound 3 Deposited 2010-02-17 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | IQX N-[5-(5-{[(2,4-dimethyl-1,3-thiazol-5-yl)sulfonyl]amino}-6-fluoropyridin-3-yl)-4-methyl-1,3-thiazol-2-yl]acetamide × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；PEG, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.60 Å R-free 0.266 |
| 3SQJ Recombinant human serum albumin from transgenic plant Deposited 2011-07-05 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–608（582 aa）
|
Not recorded | MYR MYRISTIC ACID × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；28% PEG 3350, 50mM phosphate, 150 mM KCl, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 2.05 Å R-free 0.303 |
| 3SQJ Recombinant human serum albumin from transgenic plant Deposited 2011-07-05 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
27–608（582 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；294 K；28% PEG 3350, 50mM phosphate, 150 mM KCl, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 2.05 Å R-free 0.303 |
| 3TDL Structure of human serum albumin in complex with DAUDA Deposited 2011-08-11 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 4 11D 11-({[5-(dimethylamino)naphthalen-1-yl]sulfonyl}amino)undecanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；293 K；28-32% (w/v) polyethylene glycol 3350, 50mM potassium phosphate (pH 7.5), VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.60 Å R-free 0.261 |
| 3UIV Human serum albumin-myristate-amantadine hydrochloride complex Deposited 2011-11-06 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；32% (w/v) polyethylene glycol 3350, 50mM potassium phosphate (pH 7.5), 5% glycerol, 3% DMSO, 2% MPD, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.290 |
| 3UIV Human serum albumin-myristate-amantadine hydrochloride complex Deposited 2011-11-06 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain H
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 308 (3S,5S,7S)-tricyclo[3.3.1.1~3,7~]decan-1-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；298 K；32% (w/v) polyethylene glycol 3350, 50mM potassium phosphate (pH 7.5), 5% glycerol, 3% DMSO, 2% MPD, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.20 Å R-free 0.290 |
| 4BKE Recombinant human serum albumin with palmitic acid. Synthetic cationic antimicrobial peptides bind with their hydrophobic parts to drug site II of human serum albumin Deposited 2013-04-24 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | PLM PALMITIC ACID × 7 |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 7.2；26 % PEG 3350, 50 MM KH2PO4 PH 7.2; 120 MG/ML IN 20 MM KH2PO4 AT PH 7.5 CONTAINING NOMINAL 0.1 MM PALMITIC ACID STREAK SEEDED SEEDING
|
Resolution 2.35 Å R-free 0.254 |
| 4E99 Human Serum Albumin Complex with Perfluorooctane Sulfonate Potassium Deposited 2012-03-20 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | P8S heptadecafluoro-1-octanesulfonic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION, RECRYSTALLIZATION；pH 7.5；298 K；30-36% PEG3350, 50mM potassium phosphate, pH 7.5, EVAPORATION, RECRYSTALLIZATION, temperature 298K
|
Resolution 2.30 Å R-free 0.278 |
| 4EMX Crystal structure analysis of Human Serum Albumin in complex with chloride anions at cryogenic temperature Deposited 2012-04-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；2 microL 100 mg/mL protein in 50 mM disodium/monosodium phosphate buffer and 100 mM NaCl were mixed with 2 uL 25% PEG 3350, 50 mM disodium/monosodium phosphate buffer, 100 mM NaCl, pH 7.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.30 Å R-free 0.238 |
| 4EMX Crystal structure analysis of Human Serum Albumin in complex with chloride anions at cryogenic temperature Deposited 2012-04-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；2 microL 100 mg/mL protein in 50 mM disodium/monosodium phosphate buffer and 100 mM NaCl were mixed with 2 uL 25% PEG 3350, 50 mM disodium/monosodium phosphate buffer, 100 mM NaCl, pH 7.5, vapor diffusion, hanging drop, temperature 293K
|
Resolution 2.30 Å R-free 0.238 |
| 4G03 High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin Deposited 2012-07-09 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；291 K；28-30% (w/v) PEG 3350, Sigma-Aldrich, 50mM potassium phosphate, pH 7.0, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.22 Å R-free 0.301 |
| 4G03 High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin Deposited 2012-07-09 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；291 K；28-30% (w/v) PEG 3350, Sigma-Aldrich, 50mM potassium phosphate, pH 7.0, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.22 Å R-free 0.301 |
| 4G03 High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin Deposited 2012-07-09 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
25–609（585 aa）
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；291 K；28-30% (w/v) PEG 3350, Sigma-Aldrich, 50mM potassium phosphate, pH 7.0, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.22 Å R-free 0.301 |
| 4G04 High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin Deposited 2012-07-09 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；291 K；28-30% (w/v), PEG3350, Sigma-Aldrich), 50mM potassium phosphate, pH 7.0, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.30 Å R-free 0.317 |
| 4G04 High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin Deposited 2012-07-09 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；291 K；28-30% (w/v), PEG3350, Sigma-Aldrich), 50mM potassium phosphate, pH 7.0, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.30 Å R-free 0.317 |
| 4G04 High-resolution Crystal Structural Variance Analysis between Recombinant and Wild-type Human Serum Albumin Deposited 2012-07-09 | Different construct Different mutation/modification Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein homooligomer Homooligomer；Protein × 2 PDB declaration: dimeric |
Chain A
25–609（585 aa）
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；291 K；28-30% (w/v), PEG3350, Sigma-Aldrich), 50mM potassium phosphate, pH 7.0, VAPOR DIFFUSION, temperature 291K
|
Resolution 2.30 Å R-free 0.317 |
| 4HGK Shark IgNAR variable domain Deposited 2012-10-08 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；291 K；16% PEG 2000 MME, 100 mM sodium acetate pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 3.04 Å R-free 0.266 |
| 4HGK Shark IgNAR variable domain Deposited 2012-10-08 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；291 K；16% PEG 2000 MME, 100 mM sodium acetate pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 3.04 Å R-free 0.266 |
| 4HGM Shark IgNAR Variable Domain Deposited 2012-10-08 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
25–609（585 aa）
|
Not recorded | EDO 1,2-ETHANEDIOL × 1 ACE ACETYL GROUP × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；291 K；25% PEG 2000 MME, 100 mM sodium acetate pH 4.6, VAPOR DIFFUSION, HANGING DROP, temperature 291K
|
Resolution 2.34 Å R-free 0.259 |
| 4IW1 HSA-fructose complex Deposited 2013-01-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | FRU beta-D-fructofuranose × 1 PO4 PHOSPHATE ION × 1 FUD D-fructose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；25%-30% PEG 3350, 50mM potassium phosphate, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.56 Å R-free 0.315 |
| 4IW2 HSA-glucose complex Deposited 2013-01-23 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | GLO D-glucose × 1 GLC alpha-D-glucopyranose × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；25%-30% PEG 3350, 50mM potassium phosphate, pH 7.4, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 2.41 Å R-free 0.307 |
| 4K2C HSA Ligand Free Deposited 2013-04-08 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；298 K；25-30% PEG 3350, pH 7, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.23 Å R-free 0.265 |
| 4K2C HSA Ligand Free Deposited 2013-04-08 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 7；298 K；25-30% PEG 3350, pH 7, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.23 Å R-free 0.265 |
| 4K71 Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor Deposited 2013-04-16 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–609（585 aa）
|
Mutation：V418M, T420A, E505G, V547A | SO4 SULFATE ION × 11 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；1.7 M ammonium sulfate, 0.1 M sodium citrate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.255 |
| 4K71 Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor Deposited 2013-04-16 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
25–609（585 aa）
|
Mutation：V418M, T420A, E505G, V547A | SO4 SULFATE ION × 8 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；1.7 M ammonium sulfate, 0.1 M sodium citrate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.255 |
| 4K71 Crystal structure of a high affinity Human Serum Albumin variant bound to the Neonatal Fc Receptor Deposited 2013-04-16 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 12 PDB declaration: dodecameric |
Chain A
25–609（585 aa）
Chain D
25–609（585 aa）
|
Mutation：V418M, T420A, E505G, V547A Mutation：V418M, T420A, E505G, V547A | SO4 SULFATE ION × 38 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.9；293 K；1.7 M ammonium sulfate, 0.1 M sodium citrate, pH 4.9, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.255 |
| 4L8U X-ray study of human serum albumin complexed with 9 amino camptothecin Deposited 2013-06-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | MYR MYRISTIC ACID × 5 9AZ (2S)-2-[1-amino-8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]-2-hydroxybutanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, PH 7.5, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 293K.
CRYSTALS OF THE COMPLEXES WERE OBTAINED BY STANDARD VAPOR EQUILIBRATION METHODS WITH CONDITIONS OPTIMIZED BY SCREENS VARYING PROTEIN CONCENTRATION, PH, DRUG MOLAR RATIOS, CENTERED ON THE ORIGINAL CRYSTALLIZATION HIT USING PROTOCOLS DESCRIBED PREVIOUSLY FOR THE MONOCLINIC [CARTER, ET AL., EUR. J. BIOCHEMISTRY (1994) 226: 1049-1052] AND TRICLINIC [SUGO, ET AL., PROTEIN ENG (1999) 12: 439-446] CRYSTAL FORMS.
|
Resolution 2.01 Å R-free 0.243 |
| 4L9K X-ray study of human serum albumin complexed with camptothecin Deposited 2013-06-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | EHF (2S)-2-hydroxy-2-[8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.269 |
| 4L9K X-ray study of human serum albumin complexed with camptothecin Deposited 2013-06-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | EHF (2S)-2-hydroxy-2-[8-(hydroxymethyl)-9-oxo-9,11-dihydroindolizino[1,2-b]quinolin-7-yl]butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.269 |
| 4L9Q X-ray study of human serum albumin complexed with teniposide Deposited 2013-06-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | 9TP (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-(thiophen-2-ylmethylidene)-beta-D-glucopyranoside × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.243 |
| 4L9Q X-ray study of human serum albumin complexed with teniposide Deposited 2013-06-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | 9TP (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-(thiophen-2-ylmethylidene)-beta-D-glucopyranoside × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.243 |
| 4LA0 X-ray study of human serum albumin complexed with bicalutamide Deposited 2013-06-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | 198 R-BICALUTAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, vapor diffusion, SITTING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.254 |
| 4LA0 X-ray study of human serum albumin complexed with bicalutamide Deposited 2013-06-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | 198 R-BICALUTAMIDE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, vapor diffusion, SITTING DROP, temperature 293K
|
Resolution 2.40 Å R-free 0.254 |
| 4LB2 X-ray study of human serum albumin complexed with idarubicin Deposited 2013-06-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | DM5 IDARUBICIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, vapor diffusion, SITTING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.243 |
| 4LB2 X-ray study of human serum albumin complexed with idarubicin Deposited 2013-06-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | DM5 IDARUBICIN × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, vapor diffusion, SITTING DROP, temperature 293K
|
Resolution 2.80 Å R-free 0.243 |
| 4LB9 X-ray study of human serum albumin complexed with etoposide Deposited 2013-06-20 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：UNP residues 25-609
|
Not recorded | MYR MYRISTIC ACID × 4 EVP (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG 3350, POTASSIUM PHOSPHATE, Crystals of the complexes were obtained by standard vapor equilibration methods with conditions optimized by screens varying protein concentration, pH, drug molar ratios, centered on the original crystallization hit using protocols described previously for the monoclinic [Carter, et al., Eur. J. Biochemistry (1994) 226: 1049-1052] and triclinic [Sugo, et al., Protein Eng (1999) 12: 439-446] crystal forms., pH 7.5, vapor diffusion, SITTING DROP, temperature 293K
|
Resolution 2.70 Å R-free 0.249 |
| 4N0F Human FcRn complexed with human serum albumin Deposited 2013-10-01 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain D
25–609（585 aa）
Fragment：unp residues 25-609
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å R-free 0.260 |
| 4N0F Human FcRn complexed with human serum albumin Deposited 2013-10-01 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain G
25–609（585 aa）
Fragment：unp residues 25-609
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å R-free 0.260 |
| 4N0F Human FcRn complexed with human serum albumin Deposited 2013-10-01 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain J
25–609（585 aa）
Fragment：unp residues 25-609
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å R-free 0.260 |
| 4N0F Human FcRn complexed with human serum albumin Deposited 2013-10-01 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 4 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain M
25–609（585 aa）
Fragment：unp residues 25-609
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG3350, 30 mM Sodium Acetate, pH 5.2, HSA/FcRn 10 mg/ml, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.02 Å R-free 0.260 |
| 4N0U Ternary complex between Neonatal Fc receptor, serum albumin and Fc Deposited 2013-10-02 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Other combination Heteromer；Protein × 8 PDB declaration: octameric |
Chain D
27–609（583 aa）
Fragment：serum albumin, unp residue 27-609
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 5.2；298 K；4% Tacsimate, pH 4.0, 12% PEG 3350, VAPOR DIFFUSION, temperature 298K
|
Resolution 3.80 Å R-free 0.303 |
| 4S1Y X-ray structure of human serum albumin complexed with cisplatin Deposited 2015-01-16 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | CPT Cisplatin × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；298 K；Crystals of a cisplatin/HSA adduct were obtained by soaking: more in detail, crystals of defatted HSA, grown after four weeks by sitting drop vapour diffusion method at 25 C using a reservoir solution of 30 % w/v polyethylene glycol 3350 in 50 mM potassium phosphate at pH 7.4 and protein concentration of 30 mg mL-1 (see experimental section or further details), were soaked for 24 h in a 0.005 M cisplatin solution in the same reservoir, VAPOR DIFFUSION, SITTING DROP, temperature 298K
|
Resolution 3.16 Å R-free 0.329 |
| 4Z69 Human serum albumin complexed with palmitic acid and diclofenac Deposited 2015-04-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | F15 PENTADECANOIC ACID × 3 PLM PALMITIC ACID × 2 DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；285 K；PEG 3350, potassium phosphate, glycerol, DMSO
|
Resolution 2.19 Å R-free 0.293 |
| 4Z69 Human serum albumin complexed with palmitic acid and diclofenac Deposited 2015-04-04 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain I
25–609（585 aa）
|
Not recorded | F15 PENTADECANOIC ACID × 3 PLM PALMITIC ACID × 2 DIF 2-[2,6-DICHLOROPHENYL)AMINO]BENZENEACETIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；285 K；PEG 3350, potassium phosphate, glycerol, DMSO
|
Resolution 2.19 Å R-free 0.293 |
| 5FUO Extending the half-life of a Fab fragment through generation of a humanised anti-Human Serum Albumin (HSA) Fv domain: an investigation into the correlation between affinity and serum half-life Deposited 2016-01-28 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 1；0.1 M CITRIC ACID PH 4.4, 0.1 M DI-SODIUM HYDROGEN PHOSPHATE, 38% V/V ETHANOL, 5% V/V POLYETHYLENE GLYCOL 1000
|
Resolution 3.60 Å R-free 0.254 |
| 5GIX Human serum albumin-Palmitic acid-Fe(Hn3piT)Cl2 Deposited 2016-06-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
Fragment：UNP residues 27-607
|
Not recorded | 6WF 14-piperidin-1-yl-11-oxa-13$l^{3}-thia-15,16$l^{4}-diaza-12$l^{3}-ferratetracyclo[8.7.0.0^{2,7}.0^{12,16}]heptadeca-1(10),2(7),3,5,8,13,16-heptaene × 1 PLM PALMITIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.4；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, and 4% DMSO.
|
Resolution 2.80 Å R-free 0.268 |
| 5GIX Human serum albumin-Palmitic acid-Fe(Hn3piT)Cl2 Deposited 2016-06-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
27–607（581 aa）
Fragment：UNP residues 27-607
|
Not recorded | 6WF 14-piperidin-1-yl-11-oxa-13$l^{3}-thia-15,16$l^{4}-diaza-12$l^{3}-ferratetracyclo[8.7.0.0^{2,7}.0^{12,16}]heptadeca-1(10),2(7),3,5,8,13,16-heptaene × 1 PLM PALMITIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7.4；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, and 4% DMSO.
|
Resolution 2.80 Å R-free 0.268 |
| 5GIY HSA-Palmitic acid-[RuCl5(ind)]2- Deposited 2016-06-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
Fragment：UNP residues 27-607
|
Not recorded | PLM PALMITIC ACID × 6 7GE pentakis(chloranyl)-(1~{H}-indazol-2-ium-2-yl)ruthenium(1-) × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7；293 K；28 PEG3350, 6% glycerol, 4% DMSO.
|
Resolution 2.54 Å R-free 0.279 |
| 5ID7 Crystal structure of human serum albumin in complex with phosphorodithioate derivative of myristoyl cyclic phosphatidic acid (cPA) Deposited 2016-02-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 6A4 (4S)-2-sulfanylidene-4-[(tetradecanoyloxy)methyl]-1,3,2lambda~5~-dioxaphospholane-2-thiolate × 3 PGE TRIETHYLENE GLYCOL × 2 PEG DI(HYDROXYETHYL)ETHER × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；28% PEG3350, 50 mM phosphate buffer
|
Resolution 2.26 Å R-free 0.253 |
| 5ID7 Crystal structure of human serum albumin in complex with phosphorodithioate derivative of myristoyl cyclic phosphatidic acid (cPA) Deposited 2016-02-24 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 6A4 (4S)-2-sulfanylidene-4-[(tetradecanoyloxy)methyl]-1,3,2lambda~5~-dioxaphospholane-2-thiolate × 3 PGE TRIETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；28% PEG3350, 50 mM phosphate buffer
|
Resolution 2.26 Å R-free 0.253 |
| 5IFO X-ray structure of HSA-Myr-KP1019 Deposited 2016-02-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | RU RUTHENIUM ION × 2 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；293 K；75-120 mg/ml protein, 50 mM potassium phosphate, 25-30% PEG4000, 150 mM KCl, 5 mM sodium azide
|
Resolution 3.20 Å R-free 0.262 |
| 5IJF Crystal structure of Human Serum Albumin in the presence of 0.5 mM zinc at pH 9.0 Deposited 2016-03-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
Fragment：residues 25-609
|
Not recorded | ZN ZINC ION × 1 UNL UNKNOWN LIGAND × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 9；289 K；0.2 ul of 90 mg/ml protein in 20 mM K2HPO4 pH 7.5 buffer was mixed with 0.2 ul of the well condition (0.1 M MMT Buffer pH 9.0, 23 % PEG 1500, 1 mM ZnCl2) and equilibrated against well solution in 96 Well 3 drop Crystallization Plate (Swissci)
|
Resolution 2.65 Å R-free 0.292 |
| 5UJB Structure of a Mcl-1 Inhibitor Binding to Site 3 of Human Serum Albumin Deposited 2017-01-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7；293 K；25-30% PEG3350, 50 mM K2PO4
|
Resolution 2.70 Å R-free 0.215 |
| 5UJB Structure of a Mcl-1 Inhibitor Binding to Site 3 of Human Serum Albumin Deposited 2017-01-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | 6AK 4-{8-chloro-11-[3-(4-chloro-3,5-dimethylphenoxy)propyl]-1-oxo-7-(1,3,5-trimethyl-1H-pyrazol-4-yl)-4,5-dihydro-1H-[1,4]diazepino[1,2-a]indol-2(3H)-yl}-1-methyl-1H-indole-6-carboxylic acid × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；pH 7；293 K；25-30% PEG3350, 50 mM K2PO4
|
Resolution 2.70 Å R-free 0.215 |
| 5VNW Crystal structure of Nb.b201 bound to human serum albumin Deposited 2017-05-01 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
25–609（585 aa）
|
Not recorded | GOL GLYCEROL × 3 PLM PALMITIC ACID × 1 DAO LAURIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；1,6-hexanediol, 1-butanol, 1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol, Tris(base)/BICINE pH 8.5, PEG 500 MME, PEG 20,0000, sodium chloride, HEPES pH 7.5
|
Resolution 2.60 Å R-free 0.256 |
| 5VNW Crystal structure of Nb.b201 bound to human serum albumin Deposited 2017-05-01 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
25–609（585 aa）
|
Not recorded | GOL GLYCEROL × 1 PLM PALMITIC ACID × 1 BUA butanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；293 K；1,6-hexanediol, 1-butanol, 1,2-propanediol, 2-propanol, 1,4-butanediol, 1,3-propanediol, Tris(base)/BICINE pH 8.5, PEG 500 MME, PEG 20,0000, sodium chloride, HEPES pH 7.5
|
Resolution 2.60 Å R-free 0.256 |
| 5X52 Human serum albumin complexed with octanoate and N-acetyl-L-methionine Deposited 2017-02-14 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | AME N-ACETYLMETHIONINE × 1 OCA OCTANOIC ACID (CAPRYLIC ACID) × 2 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG3350, 50 mM pottasium phosphate buffer
|
Resolution 3.00 Å R-free 0.278 |
| 5X52 Human serum albumin complexed with octanoate and N-acetyl-L-methionine Deposited 2017-02-14 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | AME N-ACETYLMETHIONINE × 1 OCA OCTANOIC ACID (CAPRYLIC ACID) × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG3350, 50 mM pottasium phosphate buffer
|
Resolution 3.00 Å R-free 0.278 |
| 5YB1 Structure and function of human serum albumin-metal agent complex Deposited 2017-09-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 7 8ZR ~{N},~{N},12-trimethyl-3$l^{3}-thia-1$l^{4},5,6$l^{4}-triaza-2$l^{3}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(8),3,6,9,11-pentaen-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG3350, MPD, DMSO
|
Resolution 2.62 Å R-free 0.278 |
| 5YB1 Structure and function of human serum albumin-metal agent complex Deposited 2017-09-02 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 7 8ZR ~{N},~{N},12-trimethyl-3$l^{3}-thia-1$l^{4},5,6$l^{4}-triaza-2$l^{3}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(8),3,6,9,11-pentaen-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG3350, MPD, DMSO
|
Resolution 2.62 Å R-free 0.278 |
| 5YOQ Human serum albumin complexed with sodium 4-phenylbutyrate Deposited 2017-10-30 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | CLT 4-PHENYL-BUTANOIC ACID × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；288 K；28%(w/v) PEG 3350, 10%(v/v) MPD, 50mM potassium phosphate buffer pH 7.0
|
Resolution 2.65 Å R-free 0.256 |
| 5YOQ Human serum albumin complexed with sodium 4-phenylbutyrate Deposited 2017-10-30 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | CLT 4-PHENYL-BUTANOIC ACID × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；288 K；28%(w/v) PEG 3350, 10%(v/v) MPD, 50mM potassium phosphate buffer pH 7.0
|
Resolution 2.65 Å R-free 0.256 |
| 5Z0B Crystal structure of plasma-derived human serum albumin Deposited 2017-12-19 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 3 PDB declaration: trimeric |
Chain A
25–609（585 aa）
Chain B
25–609（585 aa）
Chain C
25–609（585 aa）
|
Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) Non-standard monomer：Yes (specific site not provided by mmCIF) | EIC LINOLEIC ACID × 3 OCA OCTANOIC ACID (CAPRYLIC ACID) × 5 PLM PALMITIC ACID × 4 TRP TRYPTOPHAN × 3 SO4 SULFATE ION × 19 PEG DI(HYDROXYETHYL)ETHER × 13 PGE TRIETHYLENE GLYCOL × 4 PG4 TETRAETHYLENE GLYCOL × 5 1PE PENTAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 6.5；296 K；PEG600, Ammonium sulfate, MES
|
Resolution 2.17 Å R-free 0.232 |
| 6A7P Human serum albumin complexed with aripiprazole Deposited 2018-07-03 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 PO4 PHOSPHATE ION × 1 K POTASSIUM ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate buffer pH 7.0
|
Resolution 2.28 Å R-free 0.255 |
| 6A7P Human serum albumin complexed with aripiprazole Deposited 2018-07-03 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 K POTASSIUM ION × 1 PG4 TETRAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate buffer pH 7.0
|
Resolution 2.28 Å R-free 0.255 |
| 6EZQ human Serum Albumin complexed with NBD-C12 fatty acid Deposited 2017-11-16 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | C7K 12-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]dodecanoic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；292 K；Essentially defatted human serum albumin from Sigma was purified by size exclusion chromatography to obtain pure monomeric protein. The purified HSA was dissolved in 50 mM potassium phosphate, 150 mM sodium chloride (pH 7.5) and concentrated to 2 mM (140 mg/mL). The HSA solution was incubated with a six fold excess of the NBD-labelled fatty acid at 4-5 deg.C for 4 hours. The final concentration of dimethyl sulfoxide was 2% (v/v). The crystal was grown by the hanging drop vapor diffusion method using a reservoir solution containing buffer (2.5 mM potassium phosphate, 7.5 mM sodium chloride, pH 7.0), 0.3% glycerol and polyethylene glycol 3350 (~30%). For crystallization 1 uL of HSA-ligand solution was equilibrated against 1 uL of reservoir solution.
|
Resolution 2.39 Å R-free 0.298 |
| 6JE7 Crystal structure of human serum albumin crystallized by ammonium sulfate Deposited 2019-02-04 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
26–608（583 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；281 K；1.2M ammonium sulfate, 1%(v/v) 1,4-1,1,1,3,3,3-Hexafluoro-2-propanol
|
Resolution 3.90 Å R-free 0.326 |
| 6L4K Human serum albumin-Palmitic acid-Cu compound Deposited 2019-10-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 6 E5O 2-bromanyl-9-ethyl-~{N},~{N},7-trimethyl-3-thia-1$l^{4},5,6$l^{4},10-tetraza-2$l^{4}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(8),4,6,9,11-pentaen-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, and 4% DMSO.
|
Resolution 2.09 Å R-free 0.290 |
| 6L4K Human serum albumin-Palmitic acid-Cu compound Deposited 2019-10-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain I
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, and 4% DMSO.
|
Resolution 2.09 Å R-free 0.290 |
| 6M4R Structure of Human Serum Albumin Deposited 2020-03-09 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.49 Å R-free 0.274 |
| 6M4R Structure of Human Serum Albumin Deposited 2020-03-09 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.49 Å R-free 0.274 |
| 6M58 Crystal structure of a complex between human serum albumin and the antibody Fab SL335 Deposited 2020-03-10 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；PEG 4000, Tris, pH 8.5, glycerol, sodium acetate
|
Resolution 2.95 Å R-free 0.242 |
| 6M58 Crystal structure of a complex between human serum albumin and the antibody Fab SL335 Deposited 2020-03-10 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；PEG 4000, Tris, pH 8.5, glycerol, sodium acetate
|
Resolution 2.95 Å R-free 0.242 |
| 6M5D Human serum albumin (apo form) Deposited 2020-03-10 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
28–606（579 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 5.25；293 K；PEG400 potassium phosphate
|
Resolution 2.60 Å R-free 0.264 |
| 6M5E Human serum albumin with cyclic peptide dalbavancin Deposited 2020-03-10 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
26–606（581 aa）
|
Not recorded | JEF O-(O-(2-AMINOPROPYL)-O'-(2-METHOXYETHYL)POLYPROPYLENE GLYCOL 500) × 2 F8F (2S,5S)-5-azanyl-3,4,6-tris(oxidanyl)oxane-2-carboxylic acid × 1 M12 10-METHYLUNDECANOIC ACID × 1 MAN alpha-D-mannopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Sodium citrate tribasic dihydrate pH 5.0
30 % v/v Jeffamine ED-2001 pH 7.0
|
Resolution 2.80 Å R-free 0.228 |
| 6M5E Human serum albumin with cyclic peptide dalbavancin Deposited 2020-03-10 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain B
26–606（581 aa）
|
Not recorded | JEF O-(O-(2-AMINOPROPYL)-O'-(2-METHOXYETHYL)POLYPROPYLENE GLYCOL 500) × 2 F8F (2S,5S)-5-azanyl-3,4,6-tris(oxidanyl)oxane-2-carboxylic acid × 1 M12 10-METHYLUNDECANOIC ACID × 2 MAN alpha-D-mannopyranose × 1 F8X 2-amino-2-deoxy-beta-D-altropyranuronic acid × 1 WOO beta-L-allopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Sodium citrate tribasic dihydrate pH 5.0
30 % v/v Jeffamine ED-2001 pH 7.0
|
Resolution 2.80 Å R-free 0.228 |
| 6M5E Human serum albumin with cyclic peptide dalbavancin Deposited 2020-03-10 | Different construct Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 3 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain C
26–606（581 aa）
|
Not recorded | JEF O-(O-(2-AMINOPROPYL)-O'-(2-METHOXYETHYL)POLYPROPYLENE GLYCOL 500) × 2 F8F (2S,5S)-5-azanyl-3,4,6-tris(oxidanyl)oxane-2-carboxylic acid × 1 M12 10-METHYLUNDECANOIC ACID × 2 MAN alpha-D-mannopyranose × 1 F8X 2-amino-2-deoxy-beta-D-altropyranuronic acid × 1 WOO beta-L-allopyranose × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；277 K；0.1 M Sodium citrate tribasic dihydrate pH 5.0
30 % v/v Jeffamine ED-2001 pH 7.0
|
Resolution 2.80 Å R-free 0.228 |
| 6QIO Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the human growth hormone derivative somapacitan Deposited 2019-01-21 | Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–609（585 aa）
|
Mutation：V418M, T420A, E505G, V547A | MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 CYS CYSTEINE × 2 JG5 Somapacitan × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5；293 K；ammonium acetate, sodium acetate, PEG4000
|
Resolution 1.95 Å R-free 0.226 |
| 6QIP Ternary complex of FcRn ectodomain, FcRn binding optimised human serum albumin and the albumin-biniding side chain of the human growth hormone derivative somapacitan Deposited 2019-01-21 | Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 3 PDB declaration: trimeric |
Chain A
25–609（585 aa）
|
Not recorded | MES 2-(N-MORPHOLINO)-ETHANESULFONIC ACID × 1 JG5 Somapacitan × 1 BME BETA-MERCAPTOETHANOL × 1 CYS CYSTEINE × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 5.5；293 K；sodium cacodylate, PEG3350
|
Resolution 2.45 Å R-free 0.259 |
| 6R7S Human Serum Albumin, complexed with Sulfasalazine Deposited 2019-03-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | DMS DIMETHYL SULFOXIDE × 2 SO4 SULFATE ION × 1 SAS 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；HSA was dissolved in 50 mM potassium phosphate, 150 mM sodium chloride (pH 7.5) and concentrated to 2 mM (140 mg/mL). The HSA solution was incubated with a six fold excess of sulfasalazine at 4-5 degrees C for 4 hours.The crystal was grown by the hanging drop vapor diffusion method using a reservoir solution containing buffer (2.5 mM potassium phosphate, 7.5 mM sodium chloride, pH 7.0), 0.3% glycerol and polyethylene glycol 3350 (~30%). For crystallization 1 uL protein solution was equilibrated against 1 uL of reservoir solution.
|
Resolution 2.21 Å R-free 0.275 |
| 6WUW Crystal structure of Human Serum Albumin complex with JMS-053 Deposited 2020-05-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 4 UAY 7-imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione × 1 PG4 TETRAETHYLENE GLYCOL × 1 OCA OCTANOIC ACID (CAPRYLIC ACID) × 1 UNL UNKNOWN LIGAND × 1 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；311 K；Prior to crystallization, protein was incubated with myristic acid (5 mM final concentration of fatty acid) for several hours at 37 oC. Then, 0.2 ul of 100 mg/ml protein in 25 mM Tris (pH 7.4) and 50 mM NaCl were mixed with 0.2 ul of the well condition (25% PEG 3350, 50 mM K2HPO4 at pH 7.0), the crystallization plate was incubated at 37oC for several days and, after growth of the first HSA crystals, the plate was transferred to RT. JMS-053 powder (~50 ug) was added to the crystallization drop containing crystals, and then incubated for 48 h before harvesting.
|
Resolution 2.20 Å R-free 0.247 |
| 6WUW Crystal structure of Human Serum Albumin complex with JMS-053 Deposited 2020-05-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 5 UAY 7-imino-2-phenylthieno[3,2-c]pyridine-4,6(5H,7H)-dione × 1 PG4 TETRAETHYLENE GLYCOL × 1 UNL UNKNOWN LIGAND × 1 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；311 K；Prior to crystallization, protein was incubated with myristic acid (5 mM final concentration of fatty acid) for several hours at 37 oC. Then, 0.2 ul of 100 mg/ml protein in 25 mM Tris (pH 7.4) and 50 mM NaCl were mixed with 0.2 ul of the well condition (25% PEG 3350, 50 mM K2HPO4 at pH 7.0), the crystallization plate was incubated at 37oC for several days and, after growth of the first HSA crystals, the plate was transferred to RT. JMS-053 powder (~50 ug) was added to the crystallization drop containing crystals, and then incubated for 48 h before harvesting.
|
Resolution 2.20 Å R-free 0.247 |
| 6XV0 lauric acid functionalized hexamolybdoaluminate bound to human serum albumin Deposited 2020-01-21 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 M6O lauric acid functionalized hexamolybdoaluminate × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；50 mM potassium phosphate (pH 7.0), 150 mM KCl, 22-26% PEG3350, 125 mg/ml protein
|
Resolution 3.00 Å R-free 0.311 |
| 6YG9 CRYSTAL STRUCTURE OF HUMAN SERUM ALBUMIN (HSA) IN COMPLEX WITH GN-07. Deposited 2020-03-27 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 OQ5 20-[[(2~{S})-5-[2-[2-[2-[2-[2-[2-(diethylamino)-2-oxidanylidene-ethoxy]ethoxy]ethylamino]-2-oxidanylidene-ethoxy]ethoxy]ethylamino]-1-oxidanyl-1,5-bis(oxidanylidene)pentan-2-yl]amino]-20-oxidanylidene-icosanoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；293 K；Essentially defatted human serum albumin from Sigma was purified by size exclusion chromatography to obtain pure monomeric protein. The purified HSA was dissolved in 20 mM potassium phosphate (pH 7.0) and concentrated to 120 mg/mL. To the HSA solution we added 10 mM cpdX and 3 mM myristate, dissolved DMSO. The final concentration of DMSO was 5% (v/v). The crystal was grown by the hanging drop vapor diffusion method using a reservoir solution containing 50 mM sodium-potassium-phosphate (pH 7.0), and 30% polyethylene glycol 3350. For crystallization 1 uL of HSA/cpdX solution was equilibrated against 1 uL of reservoir solution. After about one-week, colorless crystals appeared.
|
Resolution 1.89 Å R-free 0.313 |
| 6ZL1 Crystal structure of human serum albumin in complex with the MCL-1 neutralizing Alphabody CMPX-383B Deposited 2020-06-30 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
1–609（609 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；310.15 K；18% (w/v) PEG 3350,
0.1 M BIS-Tris pH 6.8,
0.2 M ammonium phosphate
|
Resolution 3.27 Å R-free 0.281 |
| 6ZL1 Crystal structure of human serum albumin in complex with the MCL-1 neutralizing Alphabody CMPX-383B Deposited 2020-06-30 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain B
1–609（609 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 6.8；310.15 K；18% (w/v) PEG 3350,
0.1 M BIS-Tris pH 6.8,
0.2 M ammonium phosphate
|
Resolution 3.27 Å R-free 0.281 |
| 7A9C Human serum albumin (HSA) crystallized in the presence of yttrium (III) chloride Deposited 2020-09-01 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain AAA
25–609（585 aa）
|
Not recorded | YT3 YTTRIUM (III) ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
BATCH MODE；293 K；2mM yttrium chloride
|
Resolution 2.75 Å R-free 0.295 |
| 7AAE Crystal structure of Human serum albumin in complex with myristic acid at 2.27 Angstrom Resolution Deposited 2020-09-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain AAA
26–609（584 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 5 FMT FORMIC ACID × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；50 mM HEPES, 50 mM MOPS, 30 mM sodium fluoride, 30 mM sodium bromide, 30 mM sodium iodide, 12.5% v/v MPD, 12.5% w/v PEG 1000, 12.5% w/v PEG 3350
|
Resolution 2.27 Å R-free 0.291 |
| 7AAI Crystal structure of Human serum albumin in complex with perfluorooctanoic acid (PFOA) at 2.10 Angstrom Resolution Deposited 2020-09-04 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain AAA
26–609（584 aa）
|
Not recorded | 8PF pentadecafluorooctanoic acid × 4 MPO 3[N-MORPHOLINO]PROPANE SULFONIC ACID × 1 PGE TRIETHYLENE GLYCOL × 1 PG4 TETRAETHYLENE GLYCOL × 1 MYR MYRISTIC ACID × 4 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 6 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；50 mM HEPES, 50 mM MOPS, 30 mM diethylene glycol, 30 mM triethylene glycol (PGE), 30 mM tetraethylene glycol (PG4), 30 mM pentaethylene glycol, 12.5% v/v MPD, 12.5% w/v PEG 1000, 12.5% w/v PEG 3350
|
Resolution 2.10 Å R-free 0.289 |
| 7D6J Human serum albumin complexed with benzbromarone Deposited 2020-09-30 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | R75 [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；34% PEG 3350, 50mM K phosphate buffer pH 7.0
|
Resolution 3.29 Å R-free 0.321 |
| 7D6J Human serum albumin complexed with benzbromarone Deposited 2020-09-30 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | R75 [3,5-bis(bromanyl)-4-oxidanyl-phenyl]-(2-ethyl-1-benzofuran-3-yl)methanone × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；34% PEG 3350, 50mM K phosphate buffer pH 7.0
|
Resolution 3.29 Å R-free 0.321 |
| 7DJN Human Serum Albumin Deposited 2020-11-20 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；phosphate
|
Resolution 2.04 Å R-free 0.276 |
| 7DJN Human Serum Albumin Deposited 2020-11-20 | Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；phosphate
|
Resolution 2.04 Å R-free 0.276 |
| 7DL4 Crystal structure of human serum albumin and nitrosylruthenium complex adduct Deposited 2020-11-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | RU RUTHENIUM ION × 2 HZQ 5-chloranylquinolin-8-ol × 1 CL CHLORIDE ION × 7 NO NITRIC OXIDE × 2 GOL GLYCEROL × 4 DMS DIMETHYL SULFOXIDE × 1 PLM PALMITIC ACID × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；32% PEG3350, 50 mM pottasium phosphate buffer
|
Resolution 2.40 Å R-free 0.268 |
| 7EEK Structure of Human serum albumin-Au compound complex Deposited 2021-03-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
26–608（583 aa）
|
Not recorded | PAM PALMITOLEIC ACID × 6 J2O 11-methyl-2-oxa-4-thia-6,7-diaza-3$l^{3}-auratricyclo[7.4.0.0^{3,7}]trideca-1(13),5,9,11-tetraen-5-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350, MPD, DMSO
|
Resolution 2.50 Å |
| 7EEK Structure of Human serum albumin-Au compound complex Deposited 2021-03-18 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
26–608（583 aa）
|
Not recorded | PAM PALMITOLEIC ACID × 6 J2O 11-methyl-2-oxa-4-thia-6,7-diaza-3$l^{3}-auratricyclo[7.4.0.0^{3,7}]trideca-1(13),5,9,11-tetraen-5-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350, MPD, DMSO
|
Resolution 2.50 Å |
| 7FFR Human Serum Albumin_2 Deposited 2021-07-23 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.31 Å R-free 0.259 |
| 7FFS Human Serum Albumin_1 Deposited 2021-07-23 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.05 Å R-free 0.280 |
| 7JWN Crystal structure of Human Serum Albumin in complex with ketoprofen Deposited 2020-08-25 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
26–609（584 aa）
|
Not recorded | CYS CYSTEINE × 1 MYR MYRISTIC ACID × 3 9KL (2S)-2-[3-(benzenecarbonyl)phenyl]propanoic acid × 3 EDO 1,2-ETHANEDIOL × 1 JGE (R)-Ketoprofen × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7；310 K；Prior to crystallization, the protein at concentration of 162 mg/ml (dissolved in 50 mM Tris pH 7.4 and 20 mM NaCl) was mixed with 100 mM ketoprofen in 100% DMSO in ratio 9:1 (final ketoprofen concentration 10 mM) and incubated for several hours at 37 oC. Then, 0.2 ul of the protein solution was mixed with 0.2 ul of the well condition (24% PEG 3350, 50 mM K2HPO4 at pH 7.0). The crystallization plate was incubated at RT for 3 months, then for several days at 37 oC, and after the growth of the first HSA crystals, the plate was transferred to RT.
|
Resolution 2.60 Å R-free 0.231 |
| 7QFE Crystal structure of Human Serum albumin in complex with Gemfibrozil Deposited 2021-12-05 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 2 4TX 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid × 2 PGE TRIETHYLENE GLYCOL × 1 PG4 TETRAETHYLENE GLYCOL × 1 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 6 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 8.5；285 K；30 mM Diethylene glycol, 30 mM triethylene glycol,30 mM Tetraethylene glycol, 30 mM Pentaethylene glycol, 50 mM Bicine, 50 mM Tris, pH 8.5, 12.%%MPD, 12.5 % PEG1000, 12.5% PEG3350
|
Resolution 2.20 Å R-free 0.255 |
| 7VR0 Human Serum Albumin Deposited 2021-10-21 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 1.98 Å R-free 0.240 |
| 7VR9 Crystal structure of human serum albumin complex with aripiprazole and myristic acid Deposited 2021-10-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.30 Å R-free 0.261 |
| 7VR9 Crystal structure of human serum albumin complex with aripiprazole and myristic acid Deposited 2021-10-22 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.30 Å R-free 0.261 |
| 7WKZ Crystal structure of the HSA complex with mycophenolate and aripiprazole Deposited 2022-01-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 MOA MYCOPHENOLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.99 Å R-free 0.246 |
| 7WKZ Crystal structure of the HSA complex with mycophenolate and aripiprazole Deposited 2022-01-12 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9SC 7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 MOA MYCOPHENOLIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.99 Å R-free 0.246 |
| 7WLF Crystal structure of the HSA Fe complex Deposited 2022-01-13 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | GOL GLYCEROL × 1 9IZ 1-pyridin-2-yl-~{N}-(pyridin-2-ylmethyl)-~{N}-[(6-pyridin-2-ylpyridin-2-yl)methyl]methanamine × 1 FE FE (III) ION × 5 PLM PALMITIC ACID × 7 DMS DIMETHYL SULFOXIDE × 4 CL CHLORIDE ION × 16 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；298 K；32% PEG3350, 50 mM pottasium phosphate buffer
|
Resolution 2.40 Å R-free 0.282 |
| 7WOJ Crystal structure of HSA-Myr complex soaked with cisplatin for one week Deposited 2022-01-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | CPT Cisplatin × 9 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；297 K；26-32% PEG 3350, 50mM PB at pH 7.5
|
Resolution 2.89 Å R-free 0.284 |
| 7WOK Crystal structure of HSA soaked with cisplatin for one week Deposited 2022-01-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | CPT Cisplatin × 5 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；297 K；26-32% PEG 3350, 50mM PB at pH 7.5
|
Resolution 2.90 Å R-free 0.244 |
| 7WOK Crystal structure of HSA soaked with cisplatin for one week Deposited 2022-01-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | CPT Cisplatin × 5 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；297 K；26-32% PEG 3350, 50mM PB at pH 7.5
|
Resolution 2.90 Å R-free 0.244 |
| 7WZ9 HSA-In agent complex Deposited 2022-02-17 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 6 7Q8 16-chloranyl-~{N},~{N}-dimethyl-15-thia-1$l^{4},12$l^{4},13-triaza-16$l^{4}-indatetracyclo[8.6.0.0^{2,7}.0^{12,16}]hexadeca-1,3,5,7,9,11,13-heptaen-14-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, 4% DMSO
|
Resolution 2.83 Å R-free 0.286 |
| 7X7X Human serum albumin complex with deschloro-aripiprazole Deposited 2022-03-10 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | AJW 7-[4-(4-phenylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.4
|
Resolution 2.10 Å R-free 0.255 |
| 7X7X Human serum albumin complex with deschloro-aripiprazole Deposited 2022-03-10 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | AJW 7-[4-(4-phenylpiperazin-1-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.4；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.4
|
Resolution 2.10 Å R-free 0.255 |
| 7Y2D HSA-Cu agent complex Deposited 2022-06-09 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 6 IC4 13-methoxy-~{N},~{N}-dimethyl-2-oxa-4-thia-6,7$l^{4}-diaza-3$l^{3}-cupratricyclo[7.4.0.0^{3,7}]trideca-1(9),5,7,10,12-pentaen-5-amine × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG 3350, MPD, DMSO
|
Resolution 2.00 Å R-free 0.286 |
| 7Z57 Crystal structure of Human Serum Albumin in complex with surfactant GenX (2,3,3,3-tetrafluoro-2-(heptafluoropropoxy) propanoate) Deposited 2022-03-08 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
26–609（584 aa）
|
Not recorded | IGB (2R)-2,3,3,3-tetrakis(fluoranyl)-2-[1,1,2,2,3,3,3-heptakis(fluoranyl)propoxy]propanoic acid × 2 MPD (4S)-2-METHYL-2,4-PENTANEDIOL × 6 MYR MYRISTIC ACID × 4 BR BROMIDE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；297 K；0.09M Sodium fluoride; 0.09M Sodium
bromide; 0.09M Sodium iodide;
12.5 % v/v MPD; 12.5% PEG
1000; 12.5% w/v PEG 3350; 0.05M Tris (base); 0.05M Bicine pH 8.5
|
Resolution 2.20 Å R-free 0.264 |
| 8A9Q Computational design of stable mammalian serum albumins for bacterial expression Deposited 2022-06-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 4 RWF R-WARFARIN × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；292 K；.05M NaCl, 10% PEG 4000 and 0.05 Tris pH=8.0
|
Resolution 2.00 Å R-free 0.271 |
| 8A9Q Computational design of stable mammalian serum albumins for bacterial expression Deposited 2022-06-29 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | MYR MYRISTIC ACID × 3 RWF R-WARFARIN × 1 DAO LAURIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 8；292 K；.05M NaCl, 10% PEG 4000 and 0.05 Tris pH=8.0
|
Resolution 2.00 Å R-free 0.271 |
| 8CKS Crystal structure of Human Serum Albumin in complex with FESAN Deposited 2023-02-16 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | UZC 3,3'-commo-bis(1,2-dicarba-3-ferra-closo-dodecaborane) × 1 DMS DIMETHYL SULFOXIDE × 2 MYR MYRISTIC ACID × 3 GOL GLYCEROL × 1 OCA OCTANOIC ACID (CAPRYLIC ACID) × 3 SO4 SULFATE ION × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；281 K；1.4 M (NH4)2SO4, 1% v/v 1,1,1,3,3,3-hexafluoro-2-propanol
|
Resolution 2.60 Å R-free 0.314 |
| 8EW4 Human Serum Albumin with Cobalt (II) and Myristic Acid - crystal 1 Deposited 2022-10-21 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | CO COBALT (II) ION × 4 MYR MYRISTIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；291.15 K；200 nL 22.5% PEG Smear Low, 10% isopropanol, 100 mM Tris, pH 7.4 + 200 nL 88 mg/mL albumin, saturated myristic acid, 50 mM sodium chloride, 25 mM Tris, pH 7.4. 400 nL 45% PEG Smear Low, 20 mM cobalt chloride added 6 hours prior to harvesting.
|
Resolution 2.40 Å R-free 0.262 |
| 8EW7 Human Serum Albumin with Cobalt (II) and Myristic Acid - crystal 2 Deposited 2022-10-21 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | CO COBALT (II) ION × 9 MYR MYRISTIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；291.15 K；200 nL 18% PEG3350, 50 mM Tris, pH 7.4 + 200 nL 50 mg/mL albumin, 50% saturated myristic acid, 50 mM sodium chloride, 25 mM Tris, pH 7.4. Addition of 40% PEG3350, 50 mM Tris, 20 mM cobalt (II) chloride 6 hours prior to harvesting.
|
Resolution 3.30 Å R-free 0.272 |
| 8EY5 Human Serum Albumin with Cobalt (II) and Myristic Acid - crystal 3 Deposited 2022-10-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | CO COBALT (II) ION × 5 MYR MYRISTIC ACID × 9 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.4；291.15 K；200 nL 22.5% PEG Smear Low, 10% isopropanol, 100 mM Tris, pH 7.4 + 200 nL 88 mg/mL albumin, saturated with myristic acid, 50 mM sodium chloride, 25 mM Tris, pH 7.4. 400 nL 45% PEG Smear Low, 20 mM cobalt (II) chloride added 6 hours prior to harvesting
|
Resolution 3.10 Å R-free 0.261 |
| 8H0O Crystal structure of human serum albumin and ruthenium PZA complex adduct Deposited 2022-09-30 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | PLM PALMITIC ACID × 5 NO NITRIC OXIDE × 1 PZA PYRAZINE-2-CARBOXAMIDE × 2 RU RUTHENIUM ION × 2 CL CHLORIDE ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；sodium hydrogen phosphate
|
Resolution 2.48 Å R-free 0.294 |
| 8ISM HSA-Pt compound complex Deposited 2023-03-21 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
|
Not recorded | PLM PALMITIC ACID × 6 ZJZ 7-(2-azanyl-5-chloranyl-phenyl)-3$l^{3}-thia-5,6$l^{4}-diaza-2$l^{3}-platinatricyclo[6.4.0.0^{2,6}]dodeca-1(12),3,6,8,10-pentaen-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, 4% DMSO
|
Resolution 2.76 Å R-free 0.312 |
| 8ITR Crystal structure of lysophosphatidylcholine in complex with human serum albumin Deposited 2023-03-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–608（582 aa）
|
Not recorded | LPC [1-MYRISTOYL-GLYCEROL-3-YL]PHOSPHONYLCHOLINE × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；30% (w/v) polyethylene glycol 3350 in 50 mM potassium phosphate, pH 7.5
|
Resolution 2.44 Å R-free 0.267 |
| 8ITT Crystal structure of lysophosphatidylcholine in complex with human serum albumin and myristate Deposited 2023-03-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–606（580 aa）
|
Not recorded | MYR MYRISTIC ACID × 3 LPC [1-MYRISTOYL-GLYCEROL-3-YL]PHOSPHONYLCHOLINE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；30% (w/v) polyethylene glycol 3350 in 50 mM potassium phosphate, pH 7.5
|
Resolution 3.03 Å R-free 0.291 |
| 8ITT Crystal structure of lysophosphatidylcholine in complex with human serum albumin and myristate Deposited 2023-03-22 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
27–606（580 aa）
|
Not recorded | MYR MYRISTIC ACID × 3 LPC [1-MYRISTOYL-GLYCEROL-3-YL]PHOSPHONYLCHOLINE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；30% (w/v) polyethylene glycol 3350 in 50 mM potassium phosphate, pH 7.5
|
Resolution 3.03 Å R-free 0.291 |
| 8J8E Human serum albumin-palladium(II) agent complex Deposited 2023-05-01 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | PLM PALMITIC ACID × 6 U5U ~{N},~{N}-dimethyl-7-phenyl-3-thia-1$l^{4},5,6$l^{4}-triaza-2$l^{3}-palladatricyclo[6.4.0.0^{2,6}]dodeca-1(12),4,6,8,10-pentaen-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；30% PEG 3350, 0.05M PB 7.0, 5% G, 5% DMSO
|
Resolution 2.50 Å R-free 0.316 |
| 8J8E Human serum albumin-palladium(II) agent complex Deposited 2023-05-01 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain I
25–609（585 aa）
|
Not recorded | PLM PALMITIC ACID × 6 U5U ~{N},~{N}-dimethyl-7-phenyl-3-thia-1$l^{4},5,6$l^{4}-triaza-2$l^{3}-palladatricyclo[6.4.0.0^{2,6}]dodeca-1(12),4,6,8,10-pentaen-4-amine × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；298 K；30% PEG 3350, 0.05M PB 7.0, 5% G, 5% DMSO
|
Resolution 2.50 Å R-free 0.316 |
| 8K1Y Crystal structure of human serum albumin and ruthenium Val complex adduct Deposited 2023-07-11 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | NO NITRIC OXIDE × 1 VAL VALINE × 1 CL CHLORIDE ION × 1 RU RUTHENIUM ION × 1 PLM PALMITIC ACID × 6 GOL GLYCEROL × 2 DMS DIMETHYL SULFOXIDE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；289 K；sodium hydrogen phosphate,25%PEG3350
|
Resolution 2.15 Å R-free 0.269 |
| 8OI2 Crystal structure of Alb1 megabody in complex with human serum albumin Deposited 2023-03-22 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
27–607（581 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 8.5；293 K；0.03M Sodium fluoride, 0.03M sodium bromide, 0.03M sodium iodide, 0.1M Tris BICINE pH 8.5, 12% v/v ethylene glycol, 6% w/v PEG 8000
|
Resolution 3.30 Å R-free 0.277 |
| 8Q3F Structural studies of human serum albumin using cryo-EM up to 0.38 nm resolution Deposited 2023-08-04 | Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4；PBS buffer at pH=7.4 (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4)
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.77 Å |
| 8RCO Structure of Human Serum Albumin in complex with Aristolochic Acid II at 1.9 A resolution Deposited 2023-12-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 EDO 1,2-ETHANEDIOL × 3 GOR 6-nitronaphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；30% PEG3350, 25 mM Sodium Phosphate pH 7.0
|
Resolution 1.90 Å R-free 0.271 |
| 8RCO Structure of Human Serum Albumin in complex with Aristolochic Acid II at 1.9 A resolution Deposited 2023-12-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 EDO 1,2-ETHANEDIOL × 1 GOR 6-nitronaphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；30% PEG3350, 25 mM Sodium Phosphate pH 7.0
|
Resolution 1.90 Å R-free 0.271 |
| 8RCP Structure of Human Serum Albumin in complex with Myristic Acid Deposited 2023-12-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 8 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；25% PEG3350, 25mM Sodium Phosphate pH 7.0, Streak Seeding
|
Resolution 1.90 Å R-free 0.269 |
| 8RCP Structure of Human Serum Albumin in complex with Myristic Acid Deposited 2023-12-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 8 EDO 1,2-ETHANEDIOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；25% PEG3350, 25mM Sodium Phosphate pH 7.0, Streak Seeding
|
Resolution 1.90 Å R-free 0.269 |
| 8RGK Structure of Human Serum Albumin in complex with Aristolochic Acid at 1.9 A resolution Deposited 2023-12-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 7 EDO 1,2-ETHANEDIOL × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；34% PEG 3350, 25mM sodium Phosphate pH 7, Aristolochic Acid I.
|
Resolution 1.90 Å R-free 0.289 |
| 8RGK Structure of Human Serum Albumin in complex with Aristolochic Acid at 1.9 A resolution Deposited 2023-12-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 EDO 1,2-ETHANEDIOL × 7 GOQ 8-methoxy-6-nitro-naphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；34% PEG 3350, 25mM sodium Phosphate pH 7, Aristolochic Acid I.
|
Resolution 1.90 Å R-free 0.289 |
| 8RGL Structure of Human Serum Albumin in complex with Aristolochic Acid I at 1.9 A resolution - Optimized Deposited 2023-12-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 EDO 1,2-ETHANEDIOL × 1 GOQ 8-methoxy-6-nitro-naphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；25% PEG 3350, 25 mM Sodipum Phosphate pH 7.0
|
Resolution 1.90 Å R-free 0.281 |
| 8RGL Structure of Human Serum Albumin in complex with Aristolochic Acid I at 1.9 A resolution - Optimized Deposited 2023-12-13 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 GOQ 8-methoxy-6-nitro-naphtho[1,2-e][1,3]benzodioxole-5-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；295 K；25% PEG 3350, 25 mM Sodipum Phosphate pH 7.0
|
Resolution 1.90 Å R-free 0.281 |
| 8VAC Cryogenic electron microscopy structure of human serum albumin in complex with teniposide Deposited 2023-12-11 | Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9TP (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-(thiophen-2-ylmethylidene)-beta-D-glucopyranoside × 1 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.40 Å |
| 8VAE Cryogenic electron microscopy structure of human serum albumin in complex with salicylic acid Deposited 2023-12-11 | Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | SAL 2-HYDROXYBENZOIC ACID × 3 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å |
| 8VAF Cryogenic electron microscopy structure of apo human serum albumin Deposited 2023-12-11 | Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.4
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.50 Å |
| 8Y9S Crystal structure of nanobody MY6321 bound to human serum albumin (HSA) Deposited 2024-02-07 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
19–609（591 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M DL-Malic acid pH 7.0, 20% w/v Polyethylene glycol 3,350
|
Resolution 2.88 Å R-free 0.293 |
| 8Y9S Crystal structure of nanobody MY6321 bound to human serum albumin (HSA) Deposited 2024-02-07 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
19–609（591 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.15 M DL-Malic acid pH 7.0, 20% w/v Polyethylene glycol 3,350
|
Resolution 2.88 Å R-free 0.293 |
| 8Y9T Crystal structure of nanobody MY6322 bound to human serum albumin (HSA) Deposited 2024-02-07 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
19–609（591 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 4.6；298 K；0.1 M Sodium acetate trihydrate pH 4.6, 1.8 M Ammonium sulfate
|
Resolution 2.40 Å R-free 0.324 |
| 8Y9U Crystal structure of nanobody MY6323 bound to human serum albumin (HSA) Deposited 2024-02-07 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
19–609（591 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2 M Ammonium sulfate, 0.1 M Tris pH 8.5, 23% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å R-free 0.316 |
| 8Y9U Crystal structure of nanobody MY6323 bound to human serum albumin (HSA) Deposited 2024-02-07 | Different construct Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 2 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain C
19–609（591 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；0.2 M Ammonium sulfate, 0.1 M Tris pH 8.5, 23% w/v Polyethylene glycol 3,350
|
Resolution 3.10 Å R-free 0.316 |
| 8YG7 HSA Copper Indomethacin Complex Deposited 2024-02-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–607（581 aa）
|
Not recorded | A1D6U ~{N},~{N}-dimethyl-7-propan-2-yl-3-thia-5-aza-1,6-diazonia-2$l^{3}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(12),4,6,8,10-pentaen-4-amine × 1 IMN INDOMETHACIN × 1 PLM PALMITIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, 4% DMSO
|
Resolution 2.09 Å R-free 0.325 |
| 8YG7 HSA Copper Indomethacin Complex Deposited 2024-02-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain I
27–607（581 aa）
|
Not recorded | A1D6U ~{N},~{N}-dimethyl-7-propan-2-yl-3-thia-5-aza-1,6-diazonia-2$l^{3}-cupratricyclo[6.4.0.0^{2,6}]dodeca-1(12),4,6,8,10-pentaen-4-amine × 1 IMN INDOMETHACIN × 1 PLM PALMITIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
EVAPORATION；293 K；PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, 4% DMSO
|
Resolution 2.09 Å R-free 0.325 |
| 8YLX Single particle cryo-EM reconstruction of Oryza sativa recombinant human serum albumin Deposited 2024-03-07 | Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | OCA OCTANOIC ACID (CAPRYLIC ACID) × 3 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.18 Å |
| 8YM0 Single particle cryo-EM reconstruction of human serum albumin Deposited 2024-03-07 | Different ligand/ion Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | OCA OCTANOIC ACID (CAPRYLIC ACID) × 5 |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 8
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.05 Å |
| 8YXA Crystal structure of the HSA complex with cefazolin and myristate Deposited 2024-04-02 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | X56 Cefazolin × 1 MYR MYRISTIC ACID × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.50 Å R-free 0.319 |
| 8YXA Crystal structure of the HSA complex with cefazolin and myristate Deposited 2024-04-02 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | X56 Cefazolin × 1 MYR MYRISTIC ACID × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.50 Å R-free 0.319 |
| 8YXB Crystal structure of the HSA complex with ceftriaxone and myristate Deposited 2024-04-02 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | 9F2 Ceftriaxone × 1 MYR MYRISTIC ACID × 5 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.20 Å R-free 0.264 |
| 8YXB Crystal structure of the HSA complex with ceftriaxone and myristate Deposited 2024-04-02 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | 9F2 Ceftriaxone × 1 MYR MYRISTIC ACID × 6 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.20 Å R-free 0.264 |
| 8Z8V Crystal structure of human serum albumin in complex with ALB8(VHH) domain of ozoralizumab Deposited 2024-04-22 | Different oligomeric state Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 2 PDB declaration: dimeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；pH 4.7；293 K；100 mM SPG Buffer (pH4.7)
21 % PEG1500
|
Resolution 2.05 Å R-free 0.239 |
| 8ZPA Crystal structure of a HSA/probe complex Deposited 2024-05-29 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
19–609（591 aa）
|
Not recorded | UI8 7-$l^{3}-oxidanyl-12~{H}-[2,1]benzazaborolo[2,1-a][1,3,2]benzodiazaborinine × 1 EDO 1,2-ETHANEDIOL × 3 PLM PALMITIC ACID × 1 STE STEARIC ACID × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
MICROBATCH；pH 7.5；315 K；30% polyethylene glycol monomethyl ether 550, 0.1 M HEPES pH 7.5, 50 mM MgCl2
|
Resolution 2.59 Å R-free 0.266 |
| 9CSG Human Serum Albumin Bound to Cerastecin Compound 5e Deposited 2024-07-23 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
27–608（582 aa）
|
Not recorded | MYR MYRISTIC ACID × 6 A1AZR 2-(4-butylbenzene-1-sulfonamido)-5-(4-{3-carboxy-4-[4-(2-methoxyethyl)benzene-1-sulfonamido]anilino}-4-oxobutanamido)benzoic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；291 K；25-30% PEG 3350, 50 mM potassium phosphate, pH 7.5
|
Resolution 1.91 Å R-free 0.262 |
| 9EOD Human serum albumin with adamantene carboxylic acid Deposited 2024-03-14 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 2 PGE TRIETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 2 A1H6A adamantane-1-carboxylic acid × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；50 mM potassium phosphate pH 7.5
31 - 34 % PEG3350
Initial hollow crystals were used as seed stock for seeding experiments.
|
Resolution 1.90 Å R-free 0.268 |
| 9EOD Human serum albumin with adamantene carboxylic acid Deposited 2024-03-14 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 2 PGE TRIETHYLENE GLYCOL × 1 PEG DI(HYDROXYETHYL)ETHER × 1 A1H6A adamantane-1-carboxylic acid × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；295 K；50 mM potassium phosphate pH 7.5
31 - 34 % PEG3350
Initial hollow crystals were used as seed stock for seeding experiments.
|
Resolution 1.90 Å R-free 0.268 |
| 9EOS Human serum albumin with myristate Deposited 2024-03-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 3 PGE TRIETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；50 mM Potassium phosphate pH 7.5, 31-34 % PEG3350
|
Resolution 2.10 Å R-free 0.269 |
| 9EOS Human serum albumin with myristate Deposited 2024-03-15 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | MYR MYRISTIC ACID × 3 PG4 TETRAETHYLENE GLYCOL × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；pH 7.5；293 K；50 mM Potassium phosphate pH 7.5, 31-34 % PEG3350
|
Resolution 2.10 Å R-free 0.269 |
| 9HNB X-ray structure of the adduct formed upon reaction of the diiodido analogue of picoplatin with human serum albumin Deposited 2024-12-10 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain AAA
25–609（585 aa）
|
Not recorded | PT PLATINUM (II) ION × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7.5；293 K；25-30% PEG3350 -50 mM potassium phosphate buffer pH 7.5
|
Resolution 3.90 Å R-free 0.328 |
| 9IK3 Human Serum Albumin crystallized with T4, pH 7.5 Deposited 2024-06-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.31 Å R-free 0.271 |
| 9IK6 Human Serum Albumin crystallized with T4, pH 6.5 Deposited 2024-06-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 3 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 1.69 Å R-free 0.234 |
| 9IK7 Human Serum Albumin crystallized with T4, pH 7.5 Deposited 2024-06-26 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | T44 3,5,3',5'-TETRAIODO-L-THYRONINE × 4 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 1.97 Å R-free 0.245 |
| 9JGF Crystal structure of Human Serum Albumin (HSA) complexed with Ebselen Deposited 2024-09-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | 9JT N-phenyl-2-selanylbenzamide × 1 MYR MYRISTIC ACID × 10 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；PEG 3350, Potassium phosphate
|
Resolution 2.20 Å R-free 0.272 |
| 9JGF Crystal structure of Human Serum Albumin (HSA) complexed with Ebselen Deposited 2024-09-06 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | 9JT N-phenyl-2-selanylbenzamide × 1 MYR MYRISTIC ACID × 12 PO4 PHOSPHATE ION × 2 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；298 K；PEG 3350, Potassium phosphate
|
Resolution 2.20 Å R-free 0.272 |
| 9KQK Crystal structure of HSA in complex with AmpHecy Deposited 2024-11-26 | Different construct Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
1–609（609 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291.15 K；0.05 M KH2PO4, pH 7.0, 25% PEG3350
|
Resolution 3.05 Å R-free 0.340 |
| 9KQK Crystal structure of HSA in complex with AmpHecy Deposited 2024-11-26 | Different construct Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
1–609（609 aa）
|
Not recorded | A1EGK 2-[[6-[5-[(~{E})-2-[1-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]pyridin-1-ium-4-yl]ethenyl]thiophen-2-yl]naphthalen-2-yl]-methyl-amino]ethanol × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION；291.15 K；0.05 M KH2PO4, pH 7.0, 25% PEG3350
|
Resolution 3.05 Å R-free 0.340 |
| 9Q6H Human Serum Albumin in complex with four nanobodies: nb33, nb77, nb125 & N42 Deposited 2025-08-22 | Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.10 Å |
| 9Q6N Human Serum Albumin in complex with four nanobodies: nb118, nb68, N30 & N23 Deposited 2025-08-22 | Different construct Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
25–608（584 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 2.80 Å |
| 9Q6Y Human Serum Albumin in complex with four nanobodies: N33, nb139 & nb104 Deposited 2025-08-22 | Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 4 PDB declaration: tetrameric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.80 Å |
| 9Q6Z Human Serum Albumin in complex with four nanobodies: N33, nb139, nb39 & nb104 Deposited 2025-08-22 | Different oligomeric state Different experimental method Different experimental conditions Different structure-quality metrics | Assembly 1 Protein heterocomplex Heteromer；Protein × 5 PDB declaration: pentameric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7.5
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.70 Å |
| 9ULQ Recombinant Human Serum Albumin protein 3 Deposited 2025-04-21 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.45 Å R-free 0.287 |
| 9ULR Recombinant Human Serum Albumin protein 1 Deposited 2025-04-21 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.01 Å R-free 0.255 |
| 9ULU Recombinant Human Serum Albumin protein 2 Deposited 2025-04-21 | Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | No recorded non-water small molecule |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；298 K；PEG
|
Resolution 2.49 Å R-free 0.296 |
| 9UPD Crystal structure of human serum albumin complex with nateglinide Deposited 2025-04-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain A
25–609（585 aa）
|
Not recorded | A1L9H (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexyl)carbonylamino]propanoic acid × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.80 Å R-free 0.287 |
| 9UPD Crystal structure of human serum albumin complex with nateglinide Deposited 2025-04-28 | Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 2 Protein monomer Monomer；Protein × 1 PDB declaration: monomeric |
Chain B
25–609（585 aa）
|
Not recorded | A1L9H (2R)-3-phenyl-2-[(4-propan-2-ylcyclohexyl)carbonylamino]propanoic acid × 1 PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP；pH 7；277 K；32% PEG 3350, 50mM potassium phosphate pH 7.0
|
Resolution 2.80 Å R-free 0.287 |
| 9V61 Human Serum Albumin in I 1 2 1 space group Deposited 2025-05-26 | Different construct Different mutation/modification Different oligomeric state Different ligand/ion Different experimental conditions Different structure-quality metrics | Assembly 1 Protein homooligomer Homooligomer；Protein × 3 PDB declaration: trimeric |
Chain A
25–606（582 aa）
Chain B
25–606（582 aa）
Chain C
25–606（582 aa）
|
Not recorded | PO4 PHOSPHATE ION × 1 |
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP；293 K；ammonium phosphate monobasic, tris, sodium chloride
|
Resolution 2.50 Å R-free 0.320 |
187 other PDB entries and 270 assemblies. Open the comparison page and filter oligomeric states
View Construct and Data Evidence
| UniProt name | ALBU_HUMAN |
| Isoform | — |
| PDB entities | 1 |
| Chains and sequence ranges | Author chain A； PDBConstruct 1–585； UniProt 25–609 Author chain B； PDBConstruct 1–585； UniProt 25–609 |
